Conferences


The International Gynecologic Oncology Consensus Conference: Marrying Evidence to Practice  conference hero image

The International Gynecologic Oncology Consensus Conference: Marrying Evidence to Practice

Accreditation: 8.42 ABIM MOC II | 8.42 AMA PRA Category 1 Credit™ | 8.42 ACPE Pharmacy

Venue: Hyatt Regency Boston, One Avenue de Lafayette, Boston, MA, United States

Start Date: End Date:
Register for Conference

Official conference page for The International Gynecologic Oncology Consensus Conference: Marrying Evidence to Practice .

About The International Gynecologic Oncology Consensus Conference: Marrying Evidence to Practice

Conference
Conference attendees

Overview

Trusted by Thousands of Attendees
Across Our Events

37+

Faculty and committee

Conference program and agenda

Our Agenda

Day 1: Friday, November 6th, 2026

All timings are in Eastern Time (EDT, GMT-04:00) time.

12:00 PM - 01:00 PMRegistration, Lunch & Exhibits
01:00 PM - 01:05 PMWelcome & Meeting Introduction (Non CME Accredited)
01:05 PM - 01:20 PMBinaytara's Efforts in Improving Cancer Care Disparities - Dr. Binay Shah (Non CME Accredited)
01:20 PM - 02:25 PMSession 1a : Applying Precision Therapy in the Adjuvant Setting (Part One)

Session Chair: Anuja Jhingran, MD

01:20 PM - 01:30 PM

Molecular staging of endometrial cancer: approach to p53 abnormal tumors Carol Aghajanian, MD

01:30 PM - 01:40 PM

A critical review of the role of radiation in early-stage endometrial cancer Ann Hoge Klopp, MD

01:40 PM - 02:10 PM

Discussion

Moderators:

Anuja Jhingran, MD

Panelists:

Carol Aghajanian, MD; Ann Hoge Klopp, MD

02:10 PM - 02:25 PM

Vote (audience participation, panel vote)

02:25 PM - 02:40 PMBreak & Exhibits
02:40 PM - 03:45 PMSession 1b : Applying Precision Therapy in the Adjuvant Setting (Part One).

Session Chair: Stephanie Lherueux, MD

02:40 PM - 02:50 PM

Adjuvant PARP inhibitors: Update on long-term benefit Robert Coleman, MD

02:50 PM - 03:00 PM

Is there a role for PARPi after progression on a prior PARPi? Joyce Liu, MD

03:00 PM - 03:30 PM

Discussion

Moderators:

Stephanie Lherueux, MD

Panelists:

Robert Coleman, MD; Joyce Liu, MD

03:30 PM - 03:45 PM

Vote (audience participation, panel vote)

03:45 PM - 04:00 PMBreak & Exhibits
04:00 PM - 05:15 PMSession 2a : Novel Agents in Platinum-Resistant Ovarian Cancer.

Session Chair: Linda Duska, MD

04:00 PM - 04:10 PM

The current state of FOLR1 directed treatments: mirvetuximab and beyond Kathleen Moore, MD

04:10 PM - 04:20 PM

B96 Trial Nicoletta Colombo, MD

04:20 PM - 04:30 PM

Rosella Alexander B Olawaiye, MD

04:30 PM - 05:00 PM

Discussion

Moderators:

Linda Duska, MD

Panelists:

Kathleen Moore, MD; Nicoletta Colombo, MD; Alexander B Olawaiye, MD; Debra Richardson, MD, Other

05:00 PM - 05:15 PM

Vote (audience participation, panel vote)

Day 2: Saturday, November 7th, 2026

07:00 AM - 08:00 AMRegistration, Breakfast, and Exhibits
08:00 AM - 08:05 AMWelcome
08:05 AM - 08:30 AMBinaytara's Efforts in Improving Cancer Care Disparities
08:30 AM - 09:35 AMSession 2b : ADCs in Gynecologic Cancer.

Session Chair: Dmitriy Zamarin, MD

08:30 AM - 08:40 AM

The role of ADCs in endometrial cancer Noelle Cloven, MD

08:40 AM - 08:50 AM

Targeting HER2: is earlier better? Amanda Nickles Fader, MD

08:50 AM - 09:20 AM

Discussion

Moderators:

Dmitriy Zamarin, MD

Panelists:

Noelle Cloven, MD; Amanda Nickles Fader, MD

09:20 AM - 09:35 AM

Vote (audience participation, panel vote)

Venue and map

Accreditations and continuing education

Accreditation

Registration and pricing

Exhibitors and sponsorship